175 related articles for article (PubMed ID: 34980017)
1. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
Sano A; Sohda M; Nakazawa N; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sakai M; Ogawa H; Shirabe K; Saeki H
BMC Cancer; 2022 Jan; 22(1):22. PubMed ID: 34980017
[TBL] [Abstract][Full Text] [Related]
2. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
Matsumoto T; Yamamoto Y; Kuriona Y; Okazaki U; Kimura S; Miura K; Tsuduki T; Watanabe T; Mastumoto Y; Takatani M
BMC Cancer; 2020 Jul; 20(1):684. PubMed ID: 32698781
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.
Ishido K; Tanabe S; Katada C; Ishibashi Y; Kitahara G; Onoue M; Kubota Y; Furue Y; Wada T; Watanabe A; Kusano C
J Gastrointest Cancer; 2023 Jun; 54(2):485-491. PubMed ID: 35437632
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
7. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Satoh T; Kang YK; Chao Y; Ryu MH; Kato K; Cheol Chung H; Chen JS; Muro K; Ki Kang W; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Tanimoto M; Chen LT; Boku N
Gastric Cancer; 2020 Jan; 23(1):143-153. PubMed ID: 31087200
[TBL] [Abstract][Full Text] [Related]
8. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
Fujii H; Makiyama A; Iihara H; Okumura N; Yamamoto S; Imai T; Arakawa S; Kobayashi R; Tanaka Y; Yoshida K; Suzuki A
Anticancer Res; 2020 Dec; 40(12):7067-7075. PubMed ID: 33288604
[TBL] [Abstract][Full Text] [Related]
9. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
11. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
[TBL] [Abstract][Full Text] [Related]
12. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
[TBL] [Abstract][Full Text] [Related]
13. Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer.
Kurosaki T; Kawakami H; Mitani S; Kawabata R; Takahama T; Nonagase Y; Fumita S; Ozaki T; Chiba Y; Tamura T; Nakagawa K
In Vivo; 2020; 34(4):1921-1929. PubMed ID: 32606164
[TBL] [Abstract][Full Text] [Related]
14. Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer.
Arigami T; Matsushita D; Okubo K; Yanagita S; Ehi K; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Uenosono Y; Ishigami S; Natsugoe S
Oncology; 2020; 98(9):630-636. PubMed ID: 32428899
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Nishiyama T; Chen LT; Kang YK
Gastric Cancer; 2021 Jul; 24(4):946-958. PubMed ID: 33743112
[TBL] [Abstract][Full Text] [Related]
17. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
18. DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer.
Sunakawa Y; Inoue E; Matoba R; Kawakami H; Sato Y; Nakajima TE; Muro K; Ichikawa W; Fujii M
Future Oncol; 2019 Jul; 15(21):2441-2447. PubMed ID: 31140303
[No Abstract] [Full Text] [Related]
19. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Evaluation of the Efficacy and Adverse Effects of Nivolumab Treatment for Patients with Advanced Gastric Cancer].
Ohta A; Komatsu S; Tsuji R; Tanaka S; Kumano T; Imura K; Shimomura K; Ikeda J; Taniguchi F; Doi T; Yamada S; Tomatsuri N; Yoshida N; Shioaki Y
Gan To Kagaku Ryoho; 2020 Apr; 47(4):725-727. PubMed ID: 32389997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
